메뉴 건너뛰기




Volumn 9, Issue 12, 2009, Pages 1829-1847

Metastatic colorectal cancer: Recent advances in its clinical management

Author keywords

Bevacizumab; Biologic therapy; Cetuximab; Colorectal cancer; Liver metastases; Surgical resection

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PIRARUBICIN; PLACEBO; VASCULOTROPIN ANTIBODY;

EID: 73349129349     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.143     Document Type: Review
Times cited : (27)

References (86)
  • 2
    • 0032815641 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer. Too good to be true?
    • Borner MM. Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer. Too good to be true? Ann. Oncol. 10, 623-626 (1999).
    • (1999) Ann. Oncol , vol.10 , pp. 623-626
    • Borner, M.M.1
  • 3
    • 0018761436 scopus 로고
    • The clinical correlation of an autopsy study of recurrent colorectal cancer
    • Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann. Surg. 189, 496-502 (1979).
    • (1979) Ann. Surg , vol.189 , pp. 496-502
    • Welch, J.P.1    Donaldson, G.A.2
  • 4
    • 0033040354 scopus 로고    scopus 로고
    • Treatment of colorectal liver metastases
    • Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br. J. Surg. 86, 158-169 (1999).
    • (1999) Br. J. Surg , vol.86 , pp. 158-169
    • Geoghegan, J.G.1    Scheele, J.2
  • 5
    • 0034082744 scopus 로고    scopus 로고
    • Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized controlled trials
    • Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br. J. Cancer 82, 1789-1794 (2000).
    • (2000) Br. J. Cancer , vol.82 , pp. 1789-1794
    • Jonker, D.J.1    Maroun, J.A.2    Kocha, W.3
  • 6
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    • Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22, 1209-1214 (2004).
    • (2004) J. Clin. Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3
  • 7
    • 0038600610 scopus 로고    scopus 로고
    • Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases
    • Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol. 14(Suppl. 2), ii13-ii16 (2003).
    • (2003) Ann. Oncol , vol.14 , Issue.SUPPL. 2
    • Adam, R.1
  • 8
    • 0031052731 scopus 로고    scopus 로고
    • Liver resection for colorectal metastases
    • Fong Y, Cohen AM, Fortner JG et al. Liver resection for colorectal metastases. J. Clin. Oncol. 15, 938-946 (1997).
    • (1997) J. Clin. Oncol , vol.15 , pp. 938-946
    • Fong, Y.1    Cohen, A.M.2    Fortner, J.G.3
  • 9
    • 0032791959 scopus 로고    scopus 로고
    • Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
    • Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol. 10, 663-669 (1999).
    • (1999) Ann. Oncol , vol.10 , pp. 663-669
    • Giacchetti, S.1    Itzhaki, M.2    Gruia, G.3
  • 10
    • 20944450851 scopus 로고    scopus 로고
    • Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases
    • Pawlik TM, Scoggins CR, Zorzi D et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg. 241, 715-722 (2005).
    • (2005) Ann. Surg , vol.241 , pp. 715-722
    • Pawlik, T.M.1    Scoggins, C.R.2    Zorzi, D.3
  • 11
    • 0026006962 scopus 로고
    • Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
    • Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 9, 1967-1972 (1991).
    • (1991) J. Clin. Oncol , vol.9 , pp. 1967-1972
    • Poon, M.A.1    O'Connell, M.J.2    Wieand, H.S.3
  • 12
    • 0024390441 scopus 로고
    • Resection of hepatic metastases from colorectal cancer. Biologic perspective
    • Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann. Surg. 210, 127-138 (1989).
    • (1989) Ann. Surg , vol.210 , pp. 127-138
    • Steele Jr, G.1    Ravikumar, T.S.2
  • 13
    • 0025832661 scopus 로고
    • A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastro-intestinal Tumor Study Group Protocol 6584
    • Steele G Jr, Bleday R, Mayer RJ et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastro-intestinal Tumor Study Group Protocol 6584. J. Clin. Oncol. 9, 1105-1112 (1991).
    • (1991) J. Clin. Oncol , vol.9 , pp. 1105-1112
    • Steele Jr, G.1    Bleday, R.2    Mayer, R.J.3
  • 15
    • 0033014829 scopus 로고    scopus 로고
    • Factors influencing survival of patients undergoing hepatectomy for colorectal metastases
    • Yamamoto J, Shimada K, Kosuge T et al. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br. J. Surg. 86, 332-337 (1999).
    • (1999) Br. J. Surg , vol.86 , pp. 332-337
    • Yamamoto, J.1    Shimada, K.2    Kosuge, T.3
  • 16
    • 0036794139 scopus 로고    scopus 로고
    • Liver resection for multiple colorectal metastases: Influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival
    • Ercolani G, Grazi GL, Ravaioli M et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch. Surg. 137, 1187-1192 (2002).
    • (2002) Arch. Surg , vol.137 , pp. 1187-1192
    • Ercolani, G.1    Grazi, G.L.2    Ravaioli, M.3
  • 17
    • 0036104072 scopus 로고    scopus 로고
    • Trends in long-term survival following liver resection for hepatic colorectal metastases
    • Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg. 235, 759-766 (2002).
    • (2002) Ann. Surg , vol.235 , pp. 759-766
    • Choti, M.A.1    Sitzmann, J.V.2    Tiburi, M.F.3
  • 18
    • 7744241808 scopus 로고    scopus 로고
    • The clinical risk score: Emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases
    • Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch. Surg. 139, 1168-1172 (2004).
    • (2004) Arch. Surg , vol.139 , pp. 1168-1172
    • Mann, C.D.1    Metcalfe, M.S.2    Leopardi, L.N.3    Maddern, G.J.4
  • 19
    • 0037442149 scopus 로고    scopus 로고
    • Current treatment for liver metastases from colorectal cancer
    • Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J. Gastroenterol. 9, 193-200 (2003).
    • (2003) World J. Gastroenterol , vol.9 , pp. 193-200
    • Liu, L.X.1    Zhang, W.H.2    Jiang, H.C.3
  • 20
    • 0022516194 scopus 로고
    • Determinants of survival in liver resection for colorectal secondaries
    • Ekberg H, Tranberg KG, Andersson R et al. Determinants of survival in liver resection for colorectal secondaries. Br. J. Surg. 73, 727-731 (1986).
    • (1986) Br. J. Surg , vol.73 , pp. 727-731
    • Ekberg, H.1    Tranberg, K.G.2    Andersson, R.3
  • 21
    • 39149102132 scopus 로고    scopus 로고
    • Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: A single-center experience
    • Nuzzo G, Giuliante F, Ardito F et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery 143, 384-393 (2008).
    • (2008) Surgery , vol.143 , pp. 384-393
    • Nuzzo, G.1    Giuliante, F.2    Ardito, F.3
  • 22
    • 0037273766 scopus 로고    scopus 로고
    • Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg. Oncol. Clin. N. Am. 12, 165-192, xi (2003).
    • Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg. Oncol. Clin. N. Am. 12, 165-192, xi (2003).
  • 23
    • 1542751128 scopus 로고    scopus 로고
    • The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies
    • Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann. Surg. Oncol. 10, 1007-1011 (2003).
    • (2003) Ann. Surg. Oncol , vol.10 , pp. 1007-1011
    • Jaeck, D.1
  • 24
    • 2942545920 scopus 로고    scopus 로고
    • Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis
    • Laurent C, Sa Cunha A, Rullier E et al. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J. Am. Coll. Surg. 198, 884-891 (2004).
    • (2004) J. Am. Coll. Surg , vol.198 , pp. 884-891
    • Laurent, C.1    Sa Cunha, A.2    Rullier, E.3
  • 25
    • 38849175589 scopus 로고    scopus 로고
    • Expanding criteria for resectability of colorectal liver metastases
    • Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 13, 51-64 (2008).
    • (2008) Oncologist , vol.13 , pp. 51-64
    • Pawlik, T.M.1    Schulick, R.D.2    Choti, M.A.3
  • 26
    • 66149155832 scopus 로고    scopus 로고
    • Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 20, 985-992 (2009). Expert panel recommendations for the treatment of metastatic colorectal cancer (CRC): the majority of patients with CRC liver metastases should be treated up front with chemotherapy, irrespective of the initial resectability status of their metastases.
    • Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 20, 985-992 (2009). Expert panel recommendations for the treatment of metastatic colorectal cancer (CRC): the majority of patients with CRC liver metastases should be treated up front with chemotherapy, irrespective of the initial resectability status of their metastases.
  • 27
    • 4344619216 scopus 로고    scopus 로고
    • Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study
    • Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J. Clin. Oncol. 22, 3284-3292 (2004).
    • (2004) J. Clin. Oncol , vol.22 , pp. 3284-3292
    • Glehen, O.1    Kwiatkowski, F.2    Sugarbaker, P.H.3
  • 28
    • 59949086562 scopus 로고    scopus 로고
    • Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin
    • Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J. Clin. Oncol. 27, 681-685 (2009).
    • (2009) J. Clin. Oncol , vol.27 , pp. 681-685
    • Elias, D.1    Lefevre, J.H.2    Chevalier, J.3
  • 29
    • 0029794696 scopus 로고    scopus 로고
    • Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
    • Pioneering retrospective study of the downstaging of colorectal metastases following combination chemotherapy
    • Bismuth H, Adam R, Lévi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224, 509-520 (1996). Pioneering retrospective study of the downstaging of colorectal metastases following combination chemotherapy.
    • (1996) Ann. Surg , vol.224 , pp. 509-520
    • Bismuth, H.1    Adam, R.2    Lévi, F.3
  • 30
    • 0035018397 scopus 로고    scopus 로고
    • Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal
    • Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol. 8, 347-353 (2001).
    • (2001) Ann. Surg. Oncol , vol.8 , pp. 347-353
    • Adam, R.1    Avisar, E.2    Ariche, A.3
  • 31
    • 0036889745 scopus 로고    scopus 로고
    • Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma
    • Rivoire M, De Cian F, Meeus P et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95, 2283-2292 (2002).
    • (2002) Cancer , vol.95 , pp. 2283-2292
    • Rivoire, M.1    De Cian, F.2    Meeus, P.3
  • 32
    • 33846073122 scopus 로고    scopus 로고
    • Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases
    • Baize N, Gerard B, Bleiberg H et al. Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol. Clin. Biol. 30, 1349-1353 (2006).
    • (2006) Gastroenterol. Clin. Biol , vol.30 , pp. 1349-1353
    • Baize, N.1    Gerard, B.2    Bleiberg, H.3
  • 33
    • 63449116518 scopus 로고    scopus 로고
    • Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases
    • Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg. 249, 420-425 (2009).
    • (2009) Ann. Surg , vol.249 , pp. 420-425
    • Masi, G.1    Loupakis, F.2    Pollina, L.3
  • 34
    • 23844448040 scopus 로고    scopus 로고
    • Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates
    • Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16, 1311-1319 (2005).
    • (2005) Ann. Oncol , vol.16 , pp. 1311-1319
    • Folprecht, G.1    Grothey, A.2    Alberts, S.3
  • 35
    • 0035116969 scopus 로고    scopus 로고
    • Prospective Phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer
    • Gil-Delgado MA, Guinet F, Castaing D et al. Prospective Phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am. J. Clin. Oncol. 24, 101-105 (2001).
    • (2001) Am. J. Clin. Oncol , vol.24 , pp. 101-105
    • Gil-Delgado, M.A.1    Guinet, F.2    Castaing, D.3
  • 36
    • 0037256469 scopus 로고    scopus 로고
    • Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer
    • Wein A, Riedel C, Brückl W et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64, 131-138 (2003).
    • (2003) Oncology , vol.64 , pp. 131-138
    • Wein, A.1    Riedel, C.2    Brückl, W.3
  • 37
    • 10744229419 scopus 로고    scopus 로고
    • Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)
    • Zelek L, Bugat R, Cherqui D et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann. Oncol. 14, 1537-1542 (2003).
    • (2003) Ann. Oncol , vol.14 , pp. 1537-1542
    • Zelek, L.1    Bugat, R.2    Cherqui, D.3
  • 38
    • 2642541197 scopus 로고    scopus 로고
    • Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients
    • Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann. Oncol. 15, 933-939 (2004).
    • (2004) Ann. Oncol , vol.15 , pp. 933-939
    • Pozzo, C.1    Basso, M.2    Cassano, A.3
  • 39
    • 35348905517 scopus 로고    scopus 로고
    • Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
    • Barone C, Nuzzo G, Cassano A et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br. J. Cancer 97, 1035-1039 (2007).
    • (2007) Br. J. Cancer , vol.97 , pp. 1035-1039
    • Barone, C.1    Nuzzo, G.2    Cassano, A.3
  • 40
    • 33644819672 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study
    • Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J. Clin. Oncol. 23, 9243-9249 (2005).
    • (2005) J. Clin. Oncol , vol.23 , pp. 9243-9249
    • Alberts, S.R.1    Horvath, W.L.2    Sternfeld, W.C.3
  • 41
    • 33645269821 scopus 로고    scopus 로고
    • Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer
    • de la Cámara J, Rodriguez J, Rotellar F et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J. Clin. Oncol. 22(Suppl. 14), 3593 (2004).
    • (2004) J. Clin. Oncol , vol.22 , Issue.SUPPL. 14 , pp. 3593
    • de la Cámara, J.1    Rodriguez, J.2    Rotellar, F.3
  • 42
    • 2942638081 scopus 로고    scopus 로고
    • XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer
    • Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 22, 2084-2091 (2004).
    • (2004) J. Clin. Oncol , vol.22 , pp. 2084-2091
    • Cassidy, J.1    Tabernero, J.2    Twelves, C.3
  • 43
    • 20044365047 scopus 로고    scopus 로고
    • Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: Results of a Phase II study
    • Taïeb J, Artru P, Paye F et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a Phase II study. J. Clin. Oncol. 23, 502-509 (2005).
    • (2005) J. Clin. Oncol , vol.23 , pp. 502-509
    • Taïeb, J.1    Artru, P.2    Paye, F.3
  • 44
    • 43749090901 scopus 로고    scopus 로고
    • Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A Phase II study in colorectal cancer patients with nonresectable liver metastases
    • Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a Phase II study in colorectal cancer patients with nonresectable liver metastases. Cancer Chemother. Pharmacol. 62, 195-201 (2008).
    • (2008) Cancer Chemother. Pharmacol , vol.62 , pp. 195-201
    • Ychou, M.1    Viret, F.2    Kramar, A.3
  • 45
    • 44149107591 scopus 로고    scopus 로고
    • Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
    • Gruenberger B, Scheithauer W, Punzengruber R et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8, 120 (2008).
    • (2008) BMC Cancer , vol.8 , pp. 120
    • Gruenberger, B.1    Scheithauer, W.2    Punzengruber, R.3
  • 46
    • 0033874892 scopus 로고    scopus 로고
    • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    • Phase III clinical trial showing improved efficacy of oxaliplatin-based chemotherapy for the treatment of metastatic CRC
    • de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000). Phase III clinical trial showing improved efficacy of oxaliplatin-based chemotherapy for the treatment of metastatic CRC.
    • (2000) J. Clin. Oncol , vol.18 , pp. 2938-2947
    • de Gramont, A.1    Figer, A.2    Seymour, M.3
  • 47
    • 0034712536 scopus 로고    scopus 로고
    • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
    • Douillard J, Cunningham D, Roth A et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000).
    • (2000) Lancet , vol.355 , pp. 1041-1047
    • Douillard, J.1    Cunningham, D.2    Roth, A.3
  • 48
    • 0034727063 scopus 로고    scopus 로고
    • Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
    • Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
    • (2000) N. Engl. J. Med , vol.343 , pp. 905-914
    • Saltz, L.B.1    Cox, J.V.2    Blanke, C.3
  • 49
    • 17744418861 scopus 로고    scopus 로고
    • Randomized Phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
    • Köhne CH, Wils J, Lorenz M et al. Randomized Phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol. 21, 3721-3728 (2003).
    • (2003) J. Clin. Oncol , vol.21 , pp. 3721-3728
    • Köhne, C.H.1    Wils, J.2    Lorenz, M.3
  • 50
    • 1842569206 scopus 로고    scopus 로고
    • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    • Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
    • (2004) J. Clin. Oncol , vol.22 , pp. 23-30
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3
  • 51
    • 2542615200 scopus 로고    scopus 로고
    • Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    • André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343-2351 (2004).
    • (2004) N. Engl. J. Med , vol.350 , pp. 2343-2351
    • André, T.1    Boni, C.2    Mounedji-Boudiaf, L.3
  • 52
    • 20144389169 scopus 로고    scopus 로고
    • Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741
    • Delaunoit T, Alberts SR, Sargent DJ et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann. Oncol. 16, 425-429 (2005).
    • (2005) Ann. Oncol , vol.16 , pp. 425-429
    • Delaunoit, T.1    Alberts, S.R.2    Sargent, D.J.3
  • 53
    • 33644843853 scopus 로고    scopus 로고
    • OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study
    • Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J. Clin. Oncol. 24, 394-400 (2006).
    • (2006) J. Clin. Oncol , vol.24 , pp. 394-400
    • Tournigand, C.1    Cervantes, A.2    Figer, A.3
  • 54
    • 34249000361 scopus 로고    scopus 로고
    • Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest
    • Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25, 1670-1676 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 1670-1676
    • Falcone, A.1    Ricci, S.2    Brunetti, I.3
  • 55
    • 36048960109 scopus 로고    scopus 로고
    • Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study
    • Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol. 25, 4779-4786 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 4779-4786
    • Fuchs, C.S.1    Marshall, J.2    Mitchell, E.3
  • 56
    • 42949150908 scopus 로고    scopus 로고
    • Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    • Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26, 2006-2012 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 2006-2012
    • Cassidy, J.1    Clarke, S.2    Díaz-Rubio, E.3
  • 57
    • 40749149728 scopus 로고    scopus 로고
    • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial
    • Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371, 1007-1016 (2008).
    • (2008) Lancet , vol.371 , pp. 1007-1016
    • Nordlinger, B.1    Sorbye, H.2    Glimelius, B.3
  • 58
    • 58549090953 scopus 로고    scopus 로고
    • Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases
    • Scoggins CR, Campbell ML, Landry CS et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann. Surg. Oncol. 16, 35-41 (2009).
    • (2009) Ann. Surg. Oncol , vol.16 , pp. 35-41
    • Scoggins, C.R.1    Campbell, M.L.2    Landry, C.S.3
  • 59
    • 53049092394 scopus 로고    scopus 로고
    • Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized Phase III noninferiority study
    • Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized Phase III noninferiority study. Ann. Oncol. 19, 1720-1726 (2008).
    • (2008) Ann. Oncol , vol.19 , pp. 1720-1726
    • Rothenberg, M.L.1    Cox, J.V.2    Butts, C.3
  • 60
    • 20544478429 scopus 로고    scopus 로고
    • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized Phase II trial
    • Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. 23, 3697-7305 (2005).
    • (2005) J. Clin. Oncol , vol.23 , pp. 3697-7305
    • Kabbinavar, F.F.1    Schulz, J.2    McCleod, M.3
  • 61
    • 33644697486 scopus 로고    scopus 로고
    • Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    • Folprecht G, Lutz MP, Schöffski P et al. Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17, 450-456 (2006).
    • (2006) Ann. Oncol , vol.17 , pp. 450-456
    • Folprecht, G.1    Lutz, M.P.2    Schöffski, P.3
  • 62
    • 35648941728 scopus 로고    scopus 로고
    • Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
    • Saltz LB, Lenz HJ, Kindler HL et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25, 4557-4561 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 4557-4561
    • Saltz, L.B.1    Lenz, H.J.2    Kindler, H.L.3
  • 63
    • 36749067866 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    • Tabernero J, Van Cutsem E, Díaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25, 5225-5232 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 5225-5232
    • Tabernero, J.1    Van Cutsem, E.2    Díaz-Rubio, E.3
  • 64
    • 49049105525 scopus 로고    scopus 로고
    • Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study
    • Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol. 26, 3523-3529 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 3523-3529
    • Hochster, H.S.1    Hart, L.L.2    Ramanathan, R.K.3
  • 65
    • 42949130734 scopus 로고    scopus 로고
    • Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    • Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J. Clin. Oncol. 26, 1830-1835 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 1830-1835
    • Gruenberger, B.1    Tamandl, D.2    Schueller, J.3
  • 66
    • 46249096899 scopus 로고    scopus 로고
    • Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: A randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK
    • Borner M, Koeberle D, Von Moos R et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann. Oncol. 19, 1288-1292 (2008).
    • (2008) Ann. Oncol , vol.19 , pp. 1288-1292
    • Borner, M.1    Koeberle, D.2    Von Moos, R.3
  • 67
    • 59949091448 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    • Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663-671 (2009).
    • (2009) J. Clin. Oncol , vol.27 , pp. 663-671
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3
  • 68
    • 73349122030 scopus 로고    scopus 로고
    • Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study)
    • Folprecht G, Gruenberger T, Hartmann JT et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). J. Clin. Oncol. 27, 296 (2009).
    • (2009) J. Clin. Oncol , vol.27 , pp. 296
    • Folprecht, G.1    Gruenberger, T.2    Hartmann, J.T.3
  • 69
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Large Phase III clinical trial showing that the addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic CRC
    • Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). Large Phase III clinical trial showing that the addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic CRC.
    • (2004) N. Engl. J. Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 70
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 71
    • 63849088630 scopus 로고    scopus 로고
    • Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009). Large Phase III clinical trial of metastatic CRC showing that the benefit of cetuximab in combination therapy was limited to patients with KRAS wild-type tumors. Illustration of the use of biomarkers in patient selection.
    • Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009). Large Phase III clinical trial of metastatic CRC showing that the benefit of cetuximab in combination therapy was limited to patients with KRAS wild-type tumors. Illustration of the use of biomarkers in patient selection.
  • 72
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized Phase III study
    • Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26, 2013-2019 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Díaz-Rubio, E.3
  • 73
    • 57349117528 scopus 로고    scopus 로고
    • Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
    • Cassidy J Cunningham D, Berry SR et al. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): first BEAT and NO16966. J. Clin. Oncol. 26(Suppl.), 4022 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.SUPPL. , pp. 4022
    • Cassidy, J.1    Cunningham, D.2    Berry, S.R.3
  • 74
    • 66149120036 scopus 로고    scopus 로고
    • Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study
    • Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20(11), 1842-1847 (2009).
    • (2009) Ann. Oncol , vol.20 , Issue.11 , pp. 1842-1847
    • Van Cutsem, E.1    Rivera, F.2    Berry, S.3
  • 75
    • 56749169353 scopus 로고    scopus 로고
    • Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)
    • Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326-5334 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 5326-5334
    • Grothey, A.1    Sugrue, M.M.2    Purdie, D.M.3
  • 76
    • 44249111440 scopus 로고    scopus 로고
    • EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    • Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2311-2319 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 2311-2319
    • Sobrero, A.F.1    Maurel, J.2    Fehrenbacher, L.3
  • 77
    • 59949102930 scopus 로고    scopus 로고
    • A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    • Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672-680 (2009).
    • (2009) J. Clin. Oncol , vol.27 , pp. 672-680
    • Hecht, J.R.1    Mitchell, E.2    Chidiac, T.3
  • 78
    • 59749091477 scopus 로고    scopus 로고
    • Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer
    • Combination biologic therapy with the addition of cetuximab to capecitabine, oxaliplatin and bevacizumab resulting in significantly shorter progression-free survival and inferior quality of life. Illustrates the problems currently facing clinicians with combination biologic therapy
    • Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009). Combination biologic therapy with the addition of cetuximab to capecitabine, oxaliplatin and bevacizumab resulting in significantly shorter progression-free survival and inferior quality of life. Illustrates the problems currently facing clinicians with combination biologic therapy.
    • (2009) N. Engl. J. Med , vol.360 , pp. 563-572
    • Tol, J.1    Koopman, M.2    Cats, A.3
  • 79
    • 69549147378 scopus 로고    scopus 로고
    • A Phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
    • Abstract LBA4
    • Wolmark N, Yothers G, O'Connell MJ et al. A Phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. 27(Suppl. 18), (2009) (Abstract LBA4).
    • (2009) J. Clin. Oncol , Issue.SUPPL. 18 , pp. 27
    • Wolmark, N.1    Yothers, G.2    O'Connell, M.J.3
  • 80
    • 65349189958 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    • Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
    • (2009) J. Clin. Oncol , vol.27 , pp. 2091-2096
    • Allegra, C.J.1    Jessup, J.M.2    Somerfield, M.R.3
  • 81
    • 66849140563 scopus 로고    scopus 로고
    • PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
    • Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 27, 2622-2629 (2009).
    • (2009) J. Clin. Oncol , vol.27 , pp. 2622-2629
    • Loupakis, F.1    Pollina, L.2    Stasi, I.3
  • 82
    • 62449302407 scopus 로고    scopus 로고
    • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies
    • Sartore-Bianchi A, Martini M et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res. 69, 1851-1857 (2009).
    • (2009) Cancer Res , vol.69 , pp. 1851-1857
    • Sartore-Bianchi, A.1    Martini, M.2
  • 83
    • 68149165771 scopus 로고    scopus 로고
    • Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
    • Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer 101, 465-472 (2009).
    • (2009) Br. J. Cancer , vol.101 , pp. 465-472
    • Souglakos, J.1    Philips, J.2    Wang, R.3
  • 84
    • 67649652208 scopus 로고    scopus 로고
    • BRAF mutation in metastatic colorectal cancer
    • Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98-99 (2009).
    • (2009) N. Engl. J. Med , vol.361 , pp. 98-99
    • Tol, J.1    Nagtegaal, I.D.2    Punt, C.J.3
  • 85
    • 34147103678 scopus 로고    scopus 로고
    • Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    • van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 1658-1664
    • van Cutsem, E.1    Peeters, M.2    Siena, S.3
  • 86
    • 58949089717 scopus 로고    scopus 로고
    • Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
    • New expert recommendations on the treatment of colorectal cancer in the elderly who are understaged, undertreated and underrepresented in clinical trials
    • Papamichael D, Audisio R, Horiot JC et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann. Oncol. 20, 5-16 (2009). New expert recommendations on the treatment of colorectal cancer in the elderly who are understaged, undertreated and underrepresented in clinical trials.
    • (2009) Ann. Oncol , vol.20 , pp. 5-16
    • Papamichael, D.1    Audisio, R.2    Horiot, J.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.